My name is Gary Lelli. I’m a physician and oculoplastic surgeon specialist in New York City where I take care of patients who have eyelid, lacrimal and orbital disorders.
When patients first come to me they're feeling quite anxious. They've had a drastic change in the way that they appear and they want to know why it's happening.
It's disabling. If you're used to seeing one image and all of a sudden you begin seeing two images, you're now struggling to drive, you're worried about walking down steps and falling. It's something that's on their mind almost every minute of the day.
My most recent patient, she had told me that in addition to struggling to see, which was limiting her ability to do work. She was also routinely shutting her camera off on her Zoom calls. She became uncomfortable showing her face on camera. We're really highlighting that two things can occur here. One, she's struggling with her function. Two, now she's limiting her interaction with her colleagues because she's distraught by her appearance.
TEPEZZA really has changed the way we can think about taking care of these patients. It's our first and only FDA approved treatment for thyroid eye disease. It's been shown to be effective in decreasing proptosis, reducing diplopia for patients, improving patient's functional vision and appearance, and decreasing the inflammatory signs of the disease namely, pain and swelling.
It's really changed the way we think about the disease, but also, it's given the patients hope that there's something they can do early in the disease process that will change the course. I'm noticing on most of these patients after two or three infusions, they have significant improvement already in multiple aspects of their disease. What that allows them to do is get back to feeling like themselves again and get back to functioning again much quicker.
INDICATION AND IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.
Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.
Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.
TEPEZZA is indicated for the treatment of Thyroid Eye Disease.
Please see Full Prescribing Information for more information.